Literature DB >> 17135739

Psoriasis therapy in real life: the need for registries.

Marcus Schmitt-Egenolf1.   

Abstract

The introduction of new therapeutic options for the management of psoriasis is a challenge for the dermatology community, and new tools are needed to face this challenge. This article argues for the establishment of profession-based registries to collect solid, long-term data on the safety and effectiveness of different psoriasis treatment regimens. Managed by health care professionals, registries will be most successful if they enroll patients based on indications for treatment rather than on drugs given. This protects the evaluation process from commercial influences and allows a fair comparison of old- versus new-generation psoriasis treatments. In contrast to the patients in a registry who receive care in the natural clinical setting, subjects in randomized clinical trials (RCTs) are selected according to study criteria and may therefore not reflect the experience of patients in clinical practice. It is possible that particular risks and opportunities in the real patient population may therefore go undetected in RCTs. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17135739     DOI: 10.1159/000096196

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  6 in total

1.  Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.

Authors:  K Reich; U Mrowietz; M A Radtke; D Thaci; S J Rustenbach; C Spehr; M Augustin
Journal:  Arch Dermatol Res       Date:  2015-09-10       Impact factor: 3.017

2.  Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR).

Authors:  A B Kimball; C Leonardi; M Stahle; W Gulliver; M Chevrier; S Fakharzadeh; K Goyal; S Calabro; W Langholff; A Menter
Journal:  Br J Dermatol       Date:  2014-07-16       Impact factor: 9.302

3.  Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients.

Authors:  Paul S Calara; Rikard Althin; Katarina Steen Carlsson; Marcus Schmitt-Egenolf
Journal:  BioDrugs       Date:  2017-02       Impact factor: 5.807

4.  Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry.

Authors:  Arthur Kavanaugh; Kim Papp; Alice B Gottlieb; Elke M G J de Jong; Soumya D Chakravarty; Shelly Kafka; Wayne Langholff; Kamyar Farahi; Bhaskar Srivastava; Jose U Scher
Journal:  BMC Rheumatol       Date:  2018-09-29

5.  Rare disease registries: potential applications towards impact on development of new drug treatments.

Authors:  Marijke C Jansen-van der Weide; Charlotte M W Gaasterland; Kit C B Roes; Caridad Pontes; Roser Vives; Arantxa Sancho; Stavros Nikolakopoulos; Eric Vermeulen; Johanna H van der Lee
Journal:  Orphanet J Rare Dis       Date:  2018-09-05       Impact factor: 4.123

6.  Complete skin clearance and beyond.

Authors:  M Schmitt-Egenolf
Journal:  Br J Dermatol       Date:  2020-10-08       Impact factor: 9.302

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.